Merck's 2026 Sales Forecast of €20-21.1B Impacted by Januvia Price Cuts, Generics
MRK sits 58% above its 52-week low of $73.31.
Summary
Merck & Co. has issued a 2026 net sales forecast of €20-21.1 billion and EBITDA of €5.5-6 billion. This guidance reflects significant headwinds, including an estimated $1.5 billion revenue impact from Januvia price cuts under the Inflation Reduction Act (IRA) by 2026, as well as generic competition for Mavenclad and adverse foreign exchange effects. This specific financial outlook provides concrete details following the company's recent 10-K, which broadly warned of future revenue declines due to IRA price setting and patent expirations. The detailed impact on Januvia and other factors offers new, material information for investors to assess the company's near-term revenue trajectory. Traders will be watching for further clarity on how Merck plans to mitigate these revenue pressures, particularly through new product growth.
At the time of this announcement, MRK was trading at $115.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $286.3B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.